Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 6/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392771 | 0.83 | CHRM5 (0.50) | CHRM5ADRA2CACHENPC1KDM2B | |
| SCHEMBL14394399 | 0.81 | NPC1 (0.35) | ACHENPC1 | |
| SCHEMBL24661418 | 0.81 | CYP3A4 (0.41) | NPC1KDM2BSIGMAR1KDM4E | |
| SCHEMBL24661420 | 0.81 | CYP3A4 (0.41) | NPC1KDM2BSIGMAR1KDM4E | |
| SCHEMBL14369079 | 0.80 | NPC1 (0.34) | NPC1JAK3 | |
| SCHEMBL14392612 | 0.80 | NPC1 (0.34) | NPC1JAK3 | |
| SCHEMBL771415 | 0.80 | NPC1 (0.37) | NPC1SIGMAR1JAK3 | |
| Hydrochloric Acid SCHEMBL4426629 | 0.79 | NPC1 (0.33) | NPC1JAK3 | |
| SCHEMBL14369077 | 0.78 | NPC1 (0.33) | NPC1SIGMAR1JAK3 | |
| SCHEMBL14369074 | 0.77 | SMN1; SMN2 (0.45) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | CHRM5 244/4885ADRA2C 53/4885ACHE 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.